Atea Pharmaceuticals Q1 2024 Earnings Call Transcript

Quartr
Provided by Quartr
May 14, 2024

There are 13 speakers on the call.

Operator

Good afternoon, everyone, and welcome to the ATS Pharmaceuticals First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen only mode. Following the formal remarks, we will open the call up for your questions. I would now like to turn the call over to Janae Barnes, Senior Vice President of Investor Relations and Corporate Communications for Atea Pharma. Ms.

Operator

Barnes, please proceed.

Speaker 1

Thank you, and good afternoon, everyone, and welcome to Atea Pharmaceuticals' Q1 2024 Financial Results and Business Update Conference Call. Earlier today, we issued a press release, which outlines the topics we plan to discuss. You can access the press release as well as the slides we'll be reviewing today by going to the Investors section of our website at ir.ateapharma.com. With me today from ATEIA are Chief Executive Officer and Founder, Doctor. John Pierre Samedosi Doctor.

Speaker 1

Arun Shah Harga, Chief Medical Officer Chief Development Officer, Doctor. David Hammond Chief Financial Officer and Executive Vice President of Legal and our Chief Commercial Officer, John Vavrica. They will all be available for the Q and A portion of today's call. Before we begin the call, and as outlined on Slide 2, I would like to remind you that today's discussion will contain forward looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read.

Speaker 1

Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean Pierre.

Speaker 2

Thank you, Janet. Good afternoon, everyone, and thank you for joining us. 2024 is off to a strong start with the tremendous clinical progress we have made across our program for COVID-nineteen and HCV as you can see on Slide 3. I will begin first with an overview of our benifrostenibir program for the treatment of COVID-nineteen. Trends observed in 2024 provide further evidence that COVID is endemic and easier to stay.

Speaker 2

Variants continue to evolve and this winter we experienced a surge of infections caused by the variant GN1. Our strong operational execution led to the rapid and successful enrollment of the only global Phase 3 trial exclusively conducted in the high risk patients ahead of our guidance. We randomized 2,221 patients into the supportive care monotherapy cohort and only 74 patients into the combination therapy cohort with 77% of total patients enrolled in the United States. Strikingly, the clear preference by the investigators to enroll high risk patients in the monotherapy cohort highlights the continuing unmet medical need for new oral COVID-nineteen treatment options for these high risk patients. We believe that Benifazovy has the potential to address many of the key limitations of current COVID-nineteen therapies, including safety, tolerability and drug drug interaction.

Speaker 2

We look forward to potentially delivering Benfosbuvir to millions of patients for whom the current standard of care is not an optimal option. We anticipate top line results from SUNRISE-three in the second half of 2024. Turning now to our Phase 2 program for hepatitis C, building up the positive 98% SVR4 rate from the Lydian cohort of 60 patients. We look forward to multiple key near term milestones for this program. We are very excited about the upcoming presentation at EASL next month, which will showcase preclinical and new Phase 2 efficacy data from this leading cohort.

Speaker 2

We also look forward to reporting complete SBR12 results from this ongoing study during the second half of twenty twenty four. In addition, we are preparing for the initiation of a Phase 3 study, which we anticipate around the end of this year. We are currently finalizing the selection of the fixed dose combination tablets, which will be used in the Phase 3 program as well as for commercialization. Benifarsrevir is the most potent nucleotide inhibitor for hepatitis C treatment And Resovir is a highly potent NS5a inhibitor. We believe that the demonstrated synergistic effect of this combination can substantially improve upon the current standard of care for all patients infected with hepatitis C, including those who are the hardest to treat.

Speaker 2

And Iressa will review our HCV program in greater detail next. Importantly, we are in the strong financial position to execute our strategy with $541,500,000 of cash, cash equivalents and marketable securities at March 31 with our runway now anticipated into 2027. This is based on completing patient enrollment for Sunrise 3 ahead of schedule and our ongoing financial discipline. Andrea will provide a detailed update on Natera financial position during today's call. With that, I will now turn the call over to Erenza for an update on our global Phase 2 HCV program.

Speaker 3

Thank you, Jean Pierre. Turning to Slide 5. Despite the availability of treatment options, HCV continues to be a healthcare crisis in the U. S. HCV is a viral disease with unmet medical needs, including the need for a shorter treatment duration, fewer contraindications and less potential for drug drug interactions.

Speaker 3

New and reinfection rates annually exceed cure rates in the U. S. Where over 2,000,000 individuals are estimated to be infected. Moving to Slide 6, we believe that the combination of Beniphosfibir and rosasvir has the potential to be a best in class treatment regimen by being protease inhibitor free with a short 8 week treatment duration. It also has a low risk of drug drug interactions and there is no food effect.

Speaker 3

The proprietary market research we have conducted and KOL feedback to date supports our high confidence in this combination therapy, which has the potential to address these remaining unmet needs. Turning to Slide 7, the U. S. HCB market demand grew roughly 5% in 2023 based on the number of patients treated with the market share of the 2 key HCV treatment options atclusanimaviret remaining stable. With an estimated 2,000,000 plus people in the U.

Speaker 3

S. Living with chronic HCV, there is a large number of patients to be treated. The patient pool continues to be replenished with approximately 100,000 new chronic cases each year. We believe that the best in class profile of Benifosbuvir and rosasvir together with the anticipated future government initiatives and removal of access barriers including certain constraints by payers will increase the number of patients cured for this severe viral disease. Slide 8 outlines our Phase 2 single arm open label study of 550 milligrams of Beniphosphobir in combination with 180 milligrams of Rucesvir once daily for 8 weeks.

Speaker 3

We plan to enroll up to 280 treatment naive patients across all genotypes, including the leading cohort of 60 patients. From the initial 60 patient cohort, sustained biological response or SDR at week 4 post treatment was used as the decision criteria to continue enrollment to complete the Phase 2 study. As a reminder, the primary endpoint of the study is SBIR at week 12 for treatment and safety. Slide 9. Before we review this slide, I want to provide a brief background on the patient demographics and baseline characteristics in the leading cohort of 60 patients.

Speaker 3

It was comprised of non cirrhotic patients only. However, 10 patients had an advanced stage of fibrosis, F3, which is borderline with cirrhosis. These final results from the leading cohort were 98% SBR4 plus treatment across all genotypes enrolled. Slide 10 shows the on treatment viral kinetics of individual patient data from the leading cohort. By week 4 on treatment, all 60 patients in the leading cohort had viral load near or below the lower limit of quantification.

Speaker 3

Therefore, this very rapid kinetics across all genotypes support an 8 week regimen and compare favorably to Maviret, which is the only approved 8 week treatment for HCV. Turning to Slide 11, the combination of Beniphosfibir and Russafir was generally safe and well tolerated in the leading cohort. There were no drug related serious adverse events, no discontinuations and adverse events were mostly mild. Moving to Slide 12. To summarize our HCV efforts supported by positive leading cohort data, we initiated patient enrollment in January for the remainder of the Phase II trial.

Speaker 3

We expect to enroll up to a total of 280 patients at 50 clinical sites across 15 countries including the U. S. Looking ahead, we are very excited about upcoming data presentations at EASL, including the new Phase 2 efficacy data from the leading cohort. We expect to report complete Phase 2 SDR12 results in the second half of this year. Additionally, over the first half of twenty twenty four, we're conducting Phase 1 studies in the U.

Speaker 3

S. For the selection of the best fixed dose combination tablet, which will be evaluated in the Phase III program and used for subsequent commercialization. We anticipate that the Phase 3 program will be initiated around the end of this year. Slide 13. Next, I'll turn the call over to Janet to provide an update on our COVID program.

Speaker 4

Good afternoon, everyone. Slide 14. To reiterate Jean Pierre's earlier remarks, COVID-nineteen continues to be an established pathogen of concern with significant unmet need despite the availability of approved vaccines and antiviral treatment options. New variants continue to quickly evolve, and the most recent family of variants, nicknamed FLIRT, after their mutations include KP2, which is now the dominant variant overtaking JM1 in the United States. Our goal for COVID is to deliver a safe and effective treatment for the millions of patients for whom the current standard of care is not an optimal option.

Speaker 4

Benifossevia has a robust target profile with a low risk for drug drug interactions, favorable safety and tolerability and a distinct mechanism of action with a high barrier to resistance. In the therapeutic area with a $4,000,000,000 plus market opportunity and only 2 antiviral products approved, we believe bonyfosbuvir's compelling clinical profile and overall value proposition presents a strong opportunity for potential market expansion and uptake. Moving to Slide 15. In the Q1, we completed enrollment in SUNRISE-three, our global Phase 3 trial evaluating Benifostazia for COVID-nineteen in high risk patients. Sunrise 3 is currently the only Phase 3 program exclusively in high risk patients with hospitalization rather than symptom alleviation as the primary endpoint through day 29.

Speaker 4

The secondary endpoints measure patient outcomes through day 60 post treatment. I'm pleased to report that patient enrollment finished ahead of our guidance. This is a significant achievement and demonstrates our strong operational execution in preparation to be ready to capitalize on the JN1 variant search. We enrolled 2,221 patients in the monotherapy cohort and only 74 patients in the combination cohort. We were surprised to see such a high rate of enrollment in the monotherapy cohort.

Speaker 4

The care preference by investigators to enroll patients in the monotherapy cohort highlights the major unmet medical need for new oral COVID-nineteen treatment options for these high risk patients. In particular, we experienced strong enrollment in the U. S. Where sites were responsible for 77% of all the patients enrolled. Turning to Slide 16.

Speaker 4

I'll now review our SUNRISE III global Phase III trial. This trial enrolled high risk outpatients with mild or moderate COVID-nineteen regardless of vaccination status. Symptom onset was 5 or less days before randomization. As a reminder, this Phase III trial was randomized, double blind and placebo controlled. The study drug, including other compatible COVID-nineteen drugs at the discretion of the investigator.

Speaker 4

The primary endpoint for the study is all cause hospitalization or death through day 29 in the supportive care monotherapy population. The secondary endpoints are COVID-nineteen related hospitalizations and deaths, medically attended visits and symptom relapse through day 60 post treatment. With a fast track designation, recent supportive data presented at ESKMID and stronger than expected enrollment trends specifically seen in the monotherapy cohort, we're pleased with the execution and look forward to providing the results from our Phase III trial during the second half of twenty twenty four. Slide 17. I'll now hand the call to John to discuss the market opportunity for COVID-nineteen.

Speaker 5

Thanks, Janet. Turning to Slide 18, the U. S. Prescription demand for oral antivirals to treat COVID highly correlates with infection rates. We believe the market opportunity for oral antiviral therapeutics for COVID-nineteen will continue to remain a multi $1,000,000,000 opportunity for the long run.

Speaker 5

This is supported by IQVIA's retail prescription data indicating between $4,000,000,000 $5,000,000,000 of annual revenues between the only 2 approved oral antiviral products. A significant unmet need still exist with limitations due to drug drug interactions and tolerability with PAXLOVID and safety concerns with LIGOVRIO. We believe in beenafosivir and its potential to greatly improve the treatment landscape and bring meaningful value to patients and physicians. I will now turn the call over to Andrea to discuss Atea's financials.

Speaker 6

Thank you, John. As Jornea mentioned in her introductory remarks, earlier today, we issued a press release containing our financial results for the Q1 2024. The statement of operations and balance sheet are found on Slides 20 21. There was a marked increase in research and development expense for the Q1 of 2024 compared to the corresponding period in 2023. This increase was primarily driven by higher external spend related to the completion of enrollment of our SUNRISE 3 clinical trial and advancement of our HCV Phase 2 clinical trial.

Speaker 6

G and A expenses remained relatively consistent for the Q1 2024 compared to the Q1 2023. Interest income also remained relatively consistent for the Q1 of 2024 compared to the corresponding in 2023 due to investing in higher yield marketable securities and higher interest rates. During 2024, we anticipate our quarter over quarter R and D spend to vary as we complete SUNRISE 3 and our HCP Phase 2 study and then engage in activities to initiate the HCB Phase 3 program in the Q4 of this year. At the end of the Q1 of 2024, our cash, cash equivalent and marketable securities balance was $541,500,000 With patient enrollment completed as scheduled for Sunrise 3 and our ongoing financial discipline, we now project our cash guidance runway into 2027. I'll now hand the call back to Jean Pierre for closing remarks.

Speaker 2

Thank you, Andrea. In closing, we have made meaningful progress in the Q1 as a result of strong execution across both program for COVID-nineteen and HCV. Our current momentum positions Satya for an exciting year ahead. Indeed, we have multiple key milestones for both programs expected this year, which have the potential to drive significant shareholder value. For COVID-nineteen, they include the top line results from Sunrise 3 in the second half of 2024 and an NDA target submission expected around year end.

Speaker 2

These milestones follow recent faster than expected enrollment of almost 2,300 patients in our global Phase 3 study exclusively in the high risk patients as Janet reminded us. As part of a multi pronged approach against COVID-nineteen, we continue to also make progress with our discovery program focused on the highly differentiated second generation protease inhibitor and we expect to provide an update for this program later this year. For HCV, in the first quarter, based on the positive 98% SVR4 results in the leading cohort of 60 patients, we are now completing enrollment for up to 220 additional patients in the ongoing Phase 2 study. As Lorenzo mentioned, we are extremely excited to showcase preclinical and new Phase 2 efficacy results in support of our HCV program at EASL next June next month. Looking ahead, complete SVR12 results for all patients enrolled in the Phase 2 study are anticipated in the second half of twenty twenty four and we are optimistic that these results will reflect the strong SVR4 efficacy data that we have reported.

Speaker 2

We are targeting Phase 3 program initiation around the end of this year. I'm always impressed with the ATEIA team effort considering that we are a company with less than 80 employees successfully carrying out 2 global studies in diseases with multi $1,000,000,000 market opportunity with great efficiency and financial discipline as Andreas has shared with us. We believe that our product candidates are highly differentiated and have the opportunity if approved to fill significant unmet medical needs in the current treatment landscape with strong blockbuster potential. With that, I will turn the call back over to the operator. Thank

Speaker 7

Our first question comes from the line of Eric Joseph with JPMorgan. Your line is now open.

Speaker 8

Hi, there. It's Billy on for Eric. Thanks for taking our question. I know before you've mentioned about how in the HCV trial, you'll be enrolling cirrhotic patients. I was just wondering kind of on a percentage basis how sizable this would be of the 2 20 patients?

Speaker 2

Rexam, can you answer the question, please?

Speaker 3

Yes. Well, it depends on how many we enroll. We have targets in the protocol. And our target will be to enroll at least 10% between 10% 20%. And it's a target

Operator

we will see.

Speaker 8

Okay. Thank you. And then kind of looking a bit further ahead with the HIV trial, what exactly how would you describe the pathway for registration for this? And is this something you'd look potentially to do yourselves or look for a partner to progress?

Speaker 2

Okay. First, as you anticipate, we will have to have end of Phase 2 meeting with the regulators. We anticipate that we will need 2 trial 2 Phase 3 trials. We anticipate that 1 of the 2 very likely will be against the comparator. Since we anticipate that the trial will be including HCV, HIV, co infected patients are likely because of the drug drug interaction with Marivant.

Speaker 2

We anticipate that the regulators will agree with us that it will be a head to head against seclusa. But obviously, I cannot speak for the regulators. And we anticipate, as you have heard from Andrea, we have a very strong balance sheet. And for the Phase III clinical program, we are being in a strong position to execute ourselves on the Phase III program. And we have already operations in many countries in terms of regulatory approval for the Phase 2, which are good set to move into the Phase 3 program, including the United States.

Speaker 2

So we anticipate that we will do ourselves the Phase 3 program.

Speaker 8

Thanks for taking our questions.

Speaker 7

Thank you. One moment for our next question please. Our next question comes from the line of Matt Maxwell Square with Morgan Stanley. Your line is now open.

Speaker 9

Great. Thank you. I was wondering if you would provide any thoughts on Shionogi's recent Phase 3 update, which they missed on the primary, and their intention to meet with the FDA? Also, which secondary endpoints in the SUNRISE 3 trial would you call out as particularly important given the competitive landscape? Thank you very much.

Speaker 2

Thank you, Alex. Janet?

Speaker 4

Thank you. Yes. So with regard to the Cean OD Phase 3 trial, I think our information is much the same as yours. I think to some extent, symptom endpoint has been a place which has not been successful for companies developing antiviral drugs in the space. And so I think some of the things which are different from that trial than ours were really, I think, 1st and foremost that they selected to go after this as the primary endpoint.

Speaker 4

I think they were, it pains to point out that they did succeed on a subset

Speaker 1

of those symptoms.

Speaker 4

However, it's obviously disappointing to see them failing on that key primary endpoint. We, as I mentioned, are focusing on hospitalization because we have strong proof of principle on that from our morning trial study. And our population is different from that in that we enrolled exclusively high risk patients where hospitalization continues to be a problem. However, I think that obviously hospitalization hasn't been as common as it was previously, which is also good. So I think in regard to secondary endpoints, we have endpoints which are comparable to what others have in terms of looking for reductions in viral load in patients, looking also for potential evidence of viral rebound.

Speaker 4

This is something which has been described, I think, both in placebo and in treated patients, and we have a commitment to look at that. Also looking for evidence of emergence of resistance and also looking for hospitalizations and Medicare attended visits all the way through day 60. So I think those are the key endpoints that we're interested in.

Speaker 9

Great. Thank you.

Speaker 7

Thank you. One moment for our next question please. Our next question comes from the line of Umer Raffat with Evercore ISI. Your line is now open.

Speaker 10

Hi guys, it's John on for Umer. I would like to start with the expectations you do to Phase 3s internally. So does your current runway guidance to 27 include 2 Phase 3s for HCV? And then secondly, obviously you need to have that meeting with the FDA, but do you have a sense of what the timeline for the registrational program could be if your assumptions of a trial design are all true? How long do you think those trials would take to run?

Speaker 10

And then just lastly on the EASL data that was coming up later this month, we are going to include new data on the lead in cohort. Is that going to include long term SVR like SVR12 for that lead in cohort or just fuller details of SVR4?

Speaker 2

Thank you, John. Just to address your second part of the question, we were presenting new Phase 2 efficacy data. As you know, the embargo for abstract lift on May 22, and we would be excited to present the data on June 5. We cannot say more than that, not to break the embargo on the EASL. Andrea, can you go over in terms of the finance for the budget in terms of what we include to go all the way to 2027?

Speaker 2

And then I will take over the regulatory part. Go ahead, Andrea.

Speaker 6

Yes, John. So in answer to your question, our guidance does anticipate that we will have 2 Phase 3 trials and they will be completed during that window of time with our existing resources.

Speaker 2

And regarding timelines, let us complete the end of the Phase II and the agreement with the regulators. Obviously, first in the U. S. And in Europe, but this would be global trials, so we have to deal with several regulators. So I think we will have a better view in 2025 and share what we see as timelines, John.

Speaker 10

Makes sense. Just one final one, I guess, on Sunrise. You're guiding to data in the second half, but fair to assume that since you've got full enrollment and it's a 1 month primary endpoint, that's going to be on the early side in second half rather than the later side?

Speaker 2

Janet?

Speaker 4

I think as we mentioned, we've enrolled approximately 2,300 patients in the trial. So that's a considerable amount of data that needs to be cleaned. And we said the second half of the year, when we're nearer to knowing exactly when that is, we'll provide, I think, more specific guidance. So I think that's the best I can do for now.

Speaker 2

And don't forget, John, we need to go to 60 days also, not just 30 days. And obviously, there is a significant cleanup. I saw some numbers today, we are talking about just for symptom, I think 700,000 reports. So just to put an example, it's pretty major.

Speaker 10

Understood. Thanks.

Speaker 7

Thank you. One moment for our next question please. Our next question will come from the line of Tim Lugo with William Blair. Your line is now open.

Speaker 11

Thanks for taking my question. And I know you mentioned you didn't want to break the EASL embargo. Can you discuss though the kind of what broadly the fixed dose combo in HCV looks like? I know bendeloxibir is being dosed at 5 50 mgs once a day and rusa is 180 once a day. Is the fixed dose roughly a combination of those?

Speaker 11

What's the pill burden look like? And also yes, and let's just start there.

Speaker 2

Sure. Look, it would be a tablet and we don't want to have a huge tablet, the 1.2, 1.3 gram. So we believe that 2 tablets will be the ideal formulation, once a day, obviously. And again, we have several formulations. We have excellent data in dog under several conditions.

Speaker 2

We have completed already one fixed dose combination. We anticipate to have 1 or 2 more. Actually, the next one will start in the next couple of weeks. So as you can see, we want to maximize. Our goal is to get very close to 100% drug exposure for both BEM and Wizzasvir without any food effect.

Speaker 2

Basically, that's our goal, Tim.

Speaker 11

Okay. That makes a lot of sense. And can we expect some data, maybe not at EASL, but in the decompensated cirrhotic, I know that that seems to be a real unmet need.

Speaker 2

Well, you're right. For B compensated cirrhotic, our answer, you want to address that question?

Speaker 3

So we are now enrolling compensated cirrhotic in Phase II, but the plan for the compensated cirrhotic will be something that we'll do later.

Speaker 2

Understood. Yes. Look, Tim, as you can appreciate, okay, And I think that right now, Marivant is not indicated in the in de comp because of the presence of the PI as you know. We will have and you anticipate that, you know that unfortunately there will be some dust in the Phase III with decompensated patients. So it's clear that we want to complete the Phase III trial.

Speaker 2

And then very likely, very shortly after, it will be a head to head against EPCUSA. That patient population cannot ethically have a placebo controlled study. So definitely something that we look forward to move rapidly because of the need of those patients.

Speaker 11

Fantastic. Thank you.

Speaker 7

Thank you. One moment for our next question. Our next question comes from Roanna Ruiz with Leerink Partners. Your line is now open.

Speaker 12

Hi, everyone. This is Rosa on for Roana Ruiz. A couple of questions on HCV. Do you have a sense for how large of a safety database you'll need for registration? And thinking about the decompensated cirrhosis patient that was mentioned, can you give us

Speaker 4

a sense of the percentage of these patients

Speaker 12

as they make up like the total HCV population?

Speaker 2

Arantha, you want to address the question, please?

Speaker 3

Yes. So regarding the safety database for a combination antiviral like this, usually it's around 1,000 patients at the recommended dose and length of treatment. So that's roughly what the Phase 3 program will have to have plus what we already enrolled in Phase 2. And the second question was the percentage of decompensated patients. I cannot give you the exact percentage in the United States, but it's really less and less and it's really quite few.

Speaker 3

There is some still in usually some Asian countries, but in the United States it represents a really small amount of patients with HCV right now.

Speaker 12

Got it. Thanks. And then thinking about current rates of hospitalization for COVID-nineteen, are you guys still using the assumption of like maybe 2% to 3% currently?

Speaker 2

Janet?

Speaker 4

So we're thinking about it really in terms of achieving a statistically significant difference hospitalizations and death. And we are powered for something around a 50% difference, which is comparable to what others have seen. I think our assumptions on hospitalization are probably a little lower than that, but that is I think hospitalization has decreased. And you'll recall, we did actually expand our sample size about a year ago, I suppose, to accommodate some of that.

Speaker 12

Got it. Thanks. And then the last one on your cash runway. Does your current assumption include partnering out your COVID program, as the only option or would you consider or does that build in launching yourself potentially for COVID?

Speaker 2

Andrea?

Speaker 6

So it does anticipate that we will have a partner for COVID-nineteen. But nonetheless, we do anticipate that there will be some commercialization activities, which we individually will engage.

Speaker 2

Including large scale manufacturing, if I may add.

Speaker 12

Okay, got it. Thanks so much. That's it for us.

Speaker 2

Thank you.

Speaker 7

Thank you. I'm currently showing no further questions at this time. I'd like to hand the conference back to Mr. Jean Pierre Simodasy for closing remarks.

Speaker 2

Again, thank you all for joining our Q1 2024 earnings conference call and thank you for your continued support. Thank you.

Speaker 7

This concludes today's conference call. Thank you for your participation. You may now disconnect. Everyone, have a wonderful day.

Powered by Quartr

Key Takeaways

  • Completed enrollment in the global SUNRISE-3 Phase 3 trial for COVID-19 high-risk outpatients (2,221 monotherapy, 74 combination) ahead of guidance, with topline results expected in H2 2024 and an NDA submission targeted by year-end.
  • Benifosbuvir shows a low-risk drug-drug interaction profile, favorable safety and tolerability, and a distinct mechanism of action, positioning it to address limitations of current oral COVID-19 therapies.
  • In the Phase 2 HCV program, the leading cohort of 60 non-cirrhotic patients achieved a 98% SVR4 rate across all genotypes, with full SVR12 results slated for H2 2024 and Phase 3 initiation expected around end 2024.
  • Atea’s 8-week, protease-inhibitor-free fixed-dose combination of benifosbuvir and rosavir offers a best-in-class potential with low DDI risk, no food effect, and the ability to treat hard-to-treat HCV patients.
  • With $541.5 million in cash, cash equivalents and marketable securities at March 31, Atea’s runway extends into 2027, supporting key trial completions and commercialization preparations.
A.I. generated. May contain errors.
Earnings Conference Call
Atea Pharmaceuticals Q1 2024
00:00 / 00:00